Article Text

PDF
Anakinra treatment in patients with adult-onset Still’s disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial
  1. George D Kalliolias1,
  2. Panagiotis E Georgiou2,
  3. Ioannis A Antonopoulos3,
  4. Andrew P Andonopoulos3,
  5. Stamatis-Nick C Liossis3
  1. 1Division of Rheumatology, Department of Medicine, University of Patras Medical School and Patras University Hospital, Rion, Patras, Greece
  2. 2Division of Rheumatology, Agios Andreas Hospital, Patras, Greece
  3. 3Division of Rheumatology, Department of Medicine, University of Patras Medical School and Patras University Hospital, Rion, Patras, Greece
  1. Correspondence to:
    Dr S-N C Liossis
    Department of Medicine, Patras University Hospital, GR 26504 Rion, Patras, Greece;sliossis{at}med.upatras.gr

Statistics from Altmetric.com

Adult-onset Still’s disease (AOSD) is characterised by a group of clinical and laboratory findings indicating systemic inflammation.1 Recent data support the hypothesis that interleukin 1 is essential in mediating inflammation, particularly in recalcitrant AOSD.2,3

From December 2003 we treated 10 patients with AOSD diagnosed according to proposed criteria.4 Four of these 10 consecutive patients, 4 had refractory AOSD with persistently active disease, despite administration of high-dose steroids. Herein, we report that all four patients rapidly responded to administration of anakinra (100 mg/day) and were promptly weaned from high-dose steroids. Table 1 shows the patients’ demographics, …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.